全文获取类型
收费全文 | 1468篇 |
免费 | 84篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 88篇 |
妇产科学 | 33篇 |
基础医学 | 159篇 |
口腔科学 | 27篇 |
临床医学 | 207篇 |
内科学 | 286篇 |
皮肤病学 | 22篇 |
神经病学 | 49篇 |
特种医学 | 310篇 |
外科学 | 79篇 |
综合类 | 16篇 |
预防医学 | 64篇 |
眼科学 | 25篇 |
药学 | 55篇 |
中国医学 | 10篇 |
肿瘤学 | 131篇 |
出版年
2021年 | 14篇 |
2020年 | 5篇 |
2019年 | 10篇 |
2018年 | 15篇 |
2017年 | 11篇 |
2016年 | 14篇 |
2015年 | 20篇 |
2014年 | 24篇 |
2013年 | 41篇 |
2012年 | 40篇 |
2011年 | 31篇 |
2010年 | 45篇 |
2009年 | 33篇 |
2008年 | 30篇 |
2007年 | 43篇 |
2006年 | 34篇 |
2005年 | 38篇 |
2004年 | 38篇 |
2003年 | 21篇 |
2002年 | 18篇 |
2001年 | 32篇 |
2000年 | 25篇 |
1999年 | 35篇 |
1998年 | 96篇 |
1997年 | 72篇 |
1996年 | 85篇 |
1995年 | 54篇 |
1994年 | 56篇 |
1993年 | 67篇 |
1992年 | 19篇 |
1991年 | 22篇 |
1990年 | 16篇 |
1989年 | 50篇 |
1988年 | 39篇 |
1987年 | 50篇 |
1986年 | 28篇 |
1985年 | 39篇 |
1984年 | 29篇 |
1983年 | 17篇 |
1982年 | 26篇 |
1981年 | 28篇 |
1980年 | 28篇 |
1979年 | 8篇 |
1978年 | 18篇 |
1977年 | 19篇 |
1976年 | 24篇 |
1975年 | 15篇 |
1972年 | 5篇 |
1971年 | 6篇 |
1970年 | 4篇 |
排序方式: 共有1564条查询结果,搜索用时 15 毫秒
991.
Progenitor cell assays predict hematopoietic reconstitution after syngeneic transplantation in mice 总被引:2,自引:0,他引:2
Hematopoietic reconstitution following syngeneic bone marrow transplantation with graded doses of untreated and drug-treated bone marrow was studied in B6D2F1 mice. Granulocyte-macrophage colony- forming units (CFU-GM) and spleen colony-forming units (CFU-S) showed similar in vitro drug sensitivities. Both the speed of hematologic recovery and survival of mice transplanted with untreated or drug- treated bone marrow were directly related to the number of CFU-GM or CFU-S transplanted. Similar hematologic recovery was seen for untreated marrow transplants and treated transplants that had similar CFU-GM or CFU-S content. There is a minimum number of transplanted CFU-GM or CFU- S that allows survival of lethally irradiated mice. This number is present in a marrow transplant containing the equivalent of 5 X 10(3) untreated cells or producing one to two spleen colonies. There also exists a maximum value for the number of hematopoietic progenitors in a marrow graft, above which the rate of hematologic recovery following transplantation is rapid and no detectable increase in the rate is seen with increasing CFU-GM or CFU-S content. The presence of this maximum value for transplanted progenitors and variations in culture techniques are probably the reasons previous studies have not always shown a correlation between CFU-GM content and hematologic recovery after bone marrow transplantation. 相似文献
992.
Basic fibroblast growth factor promotes the proliferation of human megakaryocyte progenitor cells 总被引:4,自引:1,他引:4
Basic fibroblast growth factor (bFGF), a multifunctional growth factor produced by bone marrow stromal cells, is known to be a potent modulator of hematopoiesis. Because bFGF is present in both human megakaryocytes (MKs) and platelets, we have hypothesized that this growth factor might affect human megakaryocytopoiesis. To test this hypothesis, either low density bone marrow (BM) cells (LDBM), a human BM subpopulation (CD34+ DR+) enriched for the colony-forming unit megakaryocyte (CFU-MK) or a BM subpopulation (CD34+ DR-) enriched for the more primitive burst-forming unit megakaryocyte (BFU-MK) were assayed in the presence of this growth factor. The effect of bFGF on MK colony formation differed according to the cell population assayed. bFGF alone had on MK colony-stimulating activity (MK-CSA) when either CD34+ DR+ or CD34+ DR- BM cells were cloned, but exhibited MK-CSA equivalent to that of interleukin-3 (IL-3) when LDBM cells were used as the target cell population. The MK-CSA of bFGF was inhibited by the addition of neutralizing antisera to either IL-3 and/or granulocyte- macrophage colony-stimulating factor (GM-CSF) but not IL-6. The addition of excess amounts of either IL-3 or GM-CSF to cultures containing bFGF plus anti-IL-3 or anti-GM-CSF reversed the inhibition by the corresponding antisera. The addition of bFGF and IL-3 to assays containing CD34+ DR+ or CD34+ DR- cells increased the size of both CFU- MK- and BFU-MK-derived colonies, respectively, when compared with assays containing IL-3 alone. This increase in MK colony size mediated by bFGF was not affected by addition of either an anti-GM-CSF or anti- IL-6 neutralizing antisera. When LDBM cells were assayed, bFGF alone increased CFU-MK-derived colony size when compared with control values. However, this potentiation of MK colony size by bFGF could be reversed by the addition of either anti-IL-3 or anti-GM-CSF but not anti-IL-6 antisera. In addition, the effects of bFGF and IL-3 on the size of MK colonies cloned from LDBM were not additive. These results suggest that bFGF affects human megakaryocytopoiesis by directly promoting MK progenitor cell proliferation and stimulating BM accessory cells to release growth factor(s) with MK-CSA, such as IL-3 and GM-CSF. We conclude that bFGF, likely produced by cellular components of the BM microenvironment, plays an important role in the control of human megakaryocytopoiesis. 相似文献
993.
994.
995.
Previous studies have shown that tumor-specific bcr-abl mRNA can often be detected by polymerase chain reaction. (PCR) for months to years after allogeneic bone marrow transplantation (BMT) for chronic myelocytic leukemia (CML). Nevertheless, the presence of bcr-abl mRNA by itself does not invariably predict for clinical relapse post-BMT. This has led to the hypothesis that bcr-abl mRNA might be expressed in cells that have lost either proliferative or myeloid differentiation potential. To directly characterize the cells detected by PCR in patients with CML after allogeneic BMT, we first identified five individuals in whom PCR-positive cells could be detected at multiple times post-BMT. Bone marrow samples from these individuals were cultured in vitro and single erythroid, granulocytic, and macrophage colonies, each containing 50 to 100 cells, were examined for the presence of bcr-abl mRNA by PCR. PCR-positive myeloid colonies could be detected in four of five individuals in marrow samples obtained 5 to 56 months post-BMT. Overall, 7 of 135 progenitor cell colonies (5.2%) were found to be PCR-positive. The expression of bcr-abl mRNA appeared to be equally distributed among committed erythroid, macrophage, and granulocyte progenitors. These patients have now been followed-up for an additional 20 to 33 months from the time of progenitor cell PCR analysis but only one of these individuals has been found to have cytogenetic evidence of recurrent Ph+ cells. These results show that long-term persistence of PCR-detectable bcr-abl mRNA after allogeneic BMT can be caused by the persistence of CML-derived clonogenic myeloid precursors that have survived the BMT preparative regimen. These cells continue to have both proliferative and myeloid differentiation capacity in vitro. Nevertheless, these PCR-positive cells do not appear to either expand or differentiate in vivo for prolonged periods, suggesting the presence of mechanisms for suppression of residual clonogenic leukemia cells in vivo. 相似文献
996.
目的观察毛细胞丢失后耳蜗神经元延迟性死亡模式以及caspase-3的活动。方法采用3mol的庆大霉素作用离体培养的耳蜗24h,损毁全部毛细胞,分别在毛细胞丢失后1、3、5、7和14d收获样本。采用Neurofilament 200KDa标记耳蜗神经元,TRITC-labeled phalloidin标记毛细胞,免疫荧光染色观察神经元和毛细胞的存活数量,采用WesternBlot的方法检测caspase-3特异降解产物α-spectrin,间接确定caspase-3活动。结果3mol庆大霉素作用于培养的耳蜗24h,耳蜗毛细胞几乎全部消失。螺旋神经元和神经纤维的数目随培养时间的延长而减少,神经元存活从第1天的87%降至第14天的5%。神经元变小且形状不规则,在神经纤维上出现实质小体。检测caspse-3激活的特异降解带-120KDa的灰度值,发现在毛细胞丢失后24h,caspase-3活性明显高于毛细胞丢失的初时(P<0.01)。结论毛细胞丢失引起螺旋神经元死亡具有时间依赖效应,神经元出现凋亡的形态学特征,并且有caspase-3的活动。 相似文献
997.
998.
Cytokine-mediated regulation of transferrin synthesis in mouse macrophages and human T lymphocytes 总被引:2,自引:0,他引:2
Djeha A; Perez-Arellano JL; Hayes SL; Oria R; Simpson RJ; Raja KB; Brock JH 《Blood》1995,85(4):1036-1042
Transferrin (Tf) plays an important role during immunologic activation by donating iron to activated lymphocytes. Therefore, synthesis by lymphomyeloid cells has been investigated. Mouse macrophages and macrophage cell lines synthesized Tf, with levels being markedly increased by gamma-interferon (gamma-IFN) and, to a lesser extent, by interleukin-1 beta (IL-1 beta), IL-6, and tumor necrosis factor alpha (TNF alpha). Tf was also produced by phytohemagglutinin-stimulated human T cells and two T-cell lines and was increased by IL-2. Even after appropriate activation, none was synthesized by human macrophages or monocytic cell lines or by mouse T cells, T-cell lines, or thymus cells. In both species, B-lineage cell lines were negative. Tf was also synthesised by macrophages from congenitally hypotransferrinemic mice and was responsive to gamma-IFN, but levels were lower than those from normal controls. Synthesis by human and murine hepatoma cells was increased by IL-6 but unaffected by IL-1, TNF alpha, or gamma-IFN. Iron decreased synthesis by hepatoma cells but had no effect on the lymphomyeloid cells. Tf mRNA levels paralleled protein synthesis, suggesting that regulation was pre-translational. Thus, Tf synthesis by lymphomyeloid cells is regulated differently from hepatic synthesis, which is consistent with the suggestion that Tf may act in a paracrine (mouse) or autocrine (human) manner on activated lymphocytes. 相似文献
999.
Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML 总被引:2,自引:2,他引:2
Dunussi-Joannopoulos K; Weinstein HJ; Nickerson PW; Strom TB; Burakoff SJ; Croop JM; Arceci RJ 《Blood》1996,87(7):2938-2946
Recent studies have shown that tumor cells genetically modified by transduction of B7-1, a natural ligand for the T-cell costimulatory molecules CD28 and CTLA-4, are rejected in syngeneic hosts. In these reports, transformed cell lines and drug-selected cells have been used for vaccinations. To determine the effectiveness of B7-1-transduced primary acute myelogenous leukemia (AML) cells on the induction of antitumor immunity, we have studied a murine AML model in which primary AML cells were retrovirally transduced with the murine B7-1 cDNA. A defective retroviral producer clone expressing B7-1 and secreting a high titer of virus was used for infection of AML cells. Unselected transduced AML cells, expressing a high level of B7-1, were used for in vivo vaccinations. Our results show that one intravenous (IV) injection of irradiated B7-1-positive (B7-1+) AML cells can provide long-lasting (5 to 6 months) systemic immunity against subsequent challenge with wild-type AML cells. Furthermore, one exposure to irradiated B7-1+ AML cells results in rejection of leukemia by leukemic mice when the vaccination occurs in the early stages of the disease. The antileukemia immunity is CD8+ T-cell-dependent and B7/CD28-mediated, since in vivo treatment of mice with anti-CD8 monoclonal antibody or CTLA-4 Ig leads to abrogation of the specific antileukemia immune response. These results emphasize that B7-1 vaccines may have therapeutic usefulness for patients with AML. 相似文献
1000.
Gillio AP; Faulkner LB; Alter BP; Reilly L; Klafter R; Heller G; Young DC; Lipton JM; Moore MA; O'Reilly RJ 《Blood》1993,82(3):744-751
This report describes the response of eighteen Diamond-Blackfan anemia (DBA) patients to recombinant human interleukin-3 (rhIL-3). rhIL-3 was administered subcutaneously once daily on an escalating dose schedule (0.5 to 10 micrograms/kg/d). The rhIL-3 dose was escalated every 21 days until erythroid response was attained, grade III or IV nonhematologic toxicity was observed, or the maximum rhIL-3 dose was reached. Four patients experienced clinically significant erythroid responses. Two of the responders were steroid-dependent and transfusion- independent, while two were steroid-independent and transfusion- dependent. Baseline clinical or laboratory parameters, in particular in vitro bone marrow erythroid progenitor assays, were not useful in predicting rhIL-3 response. rhIL-3 administered at 5 to 10 micrograms/kg/d was associated with an increase in total white blood cell count, secondary to increases in neutrophils, eosinophils, and lymphocytes. Patients experienced a dose-dependent elevation in absolute eosinophils across the entire dose range. Two of the responding patients remain on maintenance rhIL-3, without diminution of effect at 244 and 370 + days. rhIL-3 was discontinued in the other two responders, because of the development of deep venous thrombi. 相似文献